What's Happening?
Megan Kaverman was diagnosed with heritable pulmonary arterial hypertension, a rare genetic disorder, at the age of 27 after experiencing severe fatigue and breathing difficulties. Her condition was initially dismissed by doctors due to her young age.
The disease causes the small arteries in the lungs to narrow, increasing blood pressure and straining the heart. Kaverman's diagnosis led to her sister, Katie Gusching, discovering she had the same condition after experiencing similar symptoms. Both sisters are now receiving treatment at the Cleveland Clinic and participating in clinical trials to explore new care options. They are also advocating for awareness of the disease, which affects fewer than one in a million people.
Why It's Important?
The story highlights the challenges of diagnosing rare diseases and the importance of persistence in seeking medical answers. Heritable pulmonary arterial hypertension is often diagnosed late, when patients are already in heart failure, underscoring the need for increased awareness and early detection. The sisters' advocacy efforts aim to educate others about the disease, potentially saving lives by encouraging people with unresolved cardiac symptoms to seek specialized medical advice. Their participation in clinical trials contributes to the development of new treatments, offering hope to those affected by this rare condition.
What's Next?
Both sisters continue to manage their condition with medication and are actively involved in clinical trials at the Cleveland Clinic. They plan to travel to the Dominican Republic, celebrating Gusching's birthday, marking a significant milestone in their journey towards normalcy. Their advocacy work is expected to continue, with Kaverman expressing a desire to help others by raising awareness about pulmonary hypertension. The medical community may see advancements in treatment options as research progresses, potentially improving outcomes for future patients.
